Efficacy of TABRECTA® (capmatinib) tablets
Discover clinical outcomes in treatment-naive and previously treated patients.
Testing for MET Exon 14 Skipping
Find out why, when, and how to test for biomarkers in mNSCLC, including METex14, and learn about the FDA-approved companion diagnostics for TABRECTA® (capmatinib) tablets.
Safety Profile for TABRECTA® (capmatinib) tablets
Learn about common adverse reactions and explore management strategies.
Dosing & Administration
Review the dosing details for TABRECTA® (capmatinib) tablets, including how to manage adverse reactions.
Resources
Find informational resources about TABRECTA® (capmatinib) tablets for your practice and patients.
Access & Co-pay
Novartis Oncology can help provide your patients with the right support at the right time.
Video Library
Check out the video library to learn about the mechanism of action and treatment with TABRECTA® (capmatinib) tablets.
MET, mesenchymal-epithelial transition; METex14, MET exon 14 skipping; mNSCLC, metastatic non-small cell lung cancer.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other options.